Table 3.
Rates of ≥ 50% increases of kidney function biomarkers at day two
| Cystatin C Cohort (n = 192) | Antibiotic Cohort (n = 739) | |||||
|---|---|---|---|---|---|---|
| VN + CP | VN + PT | Rate ratioa | VN + CP | VN + PT | Rate ratioa | |
| ≥ 50% increase cystatin C, n (%) | ||||||
| Crude | 17 (14.2) | 14 (19.4) | 1.37 (0.72, 2.61) | – | – | – |
| IPTW | 0.95 (0.44, 2.02) | – | ||||
| ≥ 50% increase creatinine, n (%) | ||||||
| Crude | 10 (8.3) | 14 (19.4) | 2.33 (1.09, 4.97) | 43 (9.7) | 54 (18.2) | 1.87 (1.29, 2.71) |
| IPTW | 1.86 (0.85, 4.09) | 1.55 (1.02, 2.34) | ||||
| ≥ 50% increase BUN, n (%) | ||||||
| Crude | 27 (22.5) | 19 (26.4) | 1.17 (0.70, 1.95) | 90 (20.4) | 63 (21.2) | 1.04 (0.78, 1.38) |
| IPTW | 0.99 (0.57, 1.75) | 0.88 (0.63, 1.23) | ||||
VN + PT vancomycin + piperacillin–tazobactam, VN + CP vancomycin + cefepime
aRate ratio estimated from Poisson regression accounting for person-time at risk